In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. - "Our study uncovered the crucial purpose from the KLF16/MYC regulatory axis https://jeanu110myj4.rimmablog.com/profile